The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

Taralli, Silvia; Giancipoli, Romina Grazia; Caldarella, Carmelo; Scolozzi, Valentina; Ricciardi, Sara; Cardillo, Giuseppe; Calcagni, Maria Lucia

doi:10.3390/jcm11010033

Cited by 8 publications

(5 citation statements)

References 52 publications

(202 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FDG PET has diagnostic and prognostic importance, it can identify metabolically active areas which can be correlated with imaging information, it may locate best areas for tissue biopsies and may predict prognosis in patients during treatment. A higher FDG uptake has been associated with shorter survival [38,39].…”

Section: Positron Imaging Tomography Scanmentioning

confidence: 99%

Malignant Pleural Mesothelioma

Allena,

Venkatram,

Diaz-Fuentes

2024

Challenges in Pleural Pathology - Diagnostics, Treatment and Research

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a rare tumor with a dismal prognosis that originates in the mesothelial surfaces of the pleura. The main risk factor is exposure to asbestos. Worldwide, especially in developed countries, occupational asbestos exposure has decreased significantly. Due to the long latency between exposure and development of mesothelioma, the disease is still very relevant and cases are seen sporadically. Despite advances in diagnostic imaging and clinical research, early and prompt diagnosis is challenging. Some serum tumor markers are promising but not incorporated to guidelines yet. Current treatments have been evolving very slowly in recent years; treatment focus in the use of chemotherapy, radiation and surgery. This chapter aims to present a review of malignant pleural mesothelioma to assist the practicing physician in the early recognition and evaluation of patients presenting with suspected pleural mesothelioma.

show abstract

Section: Positron Imaging Tomography Scanmentioning

confidence: 99%

Malignant Pleural Mesothelioma

Allena,

Venkatram,

Diaz-Fuentes

2024

Challenges in Pleural Pathology - Diagnostics, Treatment and Research

View full text Add to dashboard Cite

show abstract

“…This phenomenon has been demonstrated in MPM as well through PET/CT scan analysis with 2-[19 F]-fluoro-2-deoxy-D-glucose (F-FDG) tracers. In vivo, F-FDG uptake in pleural MPM shows high correlations with upregulation of GLUT1, HIF1, VEGF, CD34, Ki67, and MTOR upregulation, and poor patient prognoses; HIF-1 activation increases glucose transport (via GLUT-1) as well as glutamine and L-type amino acid transport (via LAT1) in pleural MPM [ 71 , 72 , 73 ]. Moreover, hypoxia is also known to promote the Invasive Growth program as a consequence of the activation of the MET-promoter gene by HIF-1alfa [ 74 ].…”

Section: The Role Of Microenvironmental Hypoxiamentioning

confidence: 99%

The Genes–Stemness–Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints

Stella

Marchiò

Bari

et al. 2023

IJMS

View full text Add to dashboard Cite

MPM has a uniquely poor somatic mutational landscape, mainly driven by environmental selective pressure. This feature has dramatically limited the development of effective treatment. However, genomic events are known to be associated with MPM progression, and specific genetic signatures emerge from the exceptional crosstalk between neoplastic cells and matrix components, among which one main area of focus is hypoxia. Here we discuss the novel therapeutic strategies focused on the exploitation of MPM genetic asset and its interconnection with the surrounding hypoxic microenvironment as well as transcript products and microvesicles representing both an insight into the pathogenesis and promising actionable targets.

show abstract

“…Although CT is more precise in assessing bone lesions, MRI has a superior contrast resolution, revealing more details regarding tissue characterization and tumor extension [ 2 , 4 , 6 ]. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is another complementary modality beneficial in initial staging, evaluation of response to treatment, and tumor recurrence [ 2 , 13 ].…”

Section: Role Of Imagingmentioning

confidence: 99%

A Review of Posteromedial Lesions of the Chest Wall: What Should a Chest Radiologist Know?

et al. 2022

View full text Add to dashboard Cite

A heterogeneous group of tumors can affect the posteromedial chest wall. They form diverse groups of benign and malignant (primary or secondary) pathologies that can arise from different chest wall structures, i.e., fat, muscular, vascular, osseous, or neurogenic tissues. Chest radiography is very nonspecific for the characterization of chest wall lesions. The modality of choice for the initial assessment of the chest wall lesions is computed tomography (CT). More advanced cross-sectional modalities such as magnetic resonance imaging (MRI) and positron emission tomography (PET) with fluorodeoxyglucose are usually used for further characterization, staging, treatment response, and assessment of recurrence. A systematic approach based on age, clinical history, and radiologic findings is required for correct diagnosis. It is essential for radiologists to be familiar with the spectrum of lesions that might affect the posteromedial chest wall and their characteristic imaging features. Although the imaging findings of these tumors can be nonspecific, cross-sectional imaging helps to limit the differential diagnosis and determine the further diagnostic investigation (e.g., image-guided biopsy). Specific imaging findings, e.g., location, mineralization, enhancement pattern, and local invasion, occasionally allow a particular diagnosis. This article reviews the posteromedial chest wall anatomy and different pathologies. We provide a combination of location and imaging features of each pathology. We will also explore the role of imaging and its strengths and limitations for diagnosing posteromedial chest wall lesions.

show abstract

The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

Cited by 8 publications

References 52 publications

Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma

The Genes–Stemness–Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints

A Review of Posteromedial Lesions of the Chest Wall: What Should a Chest Radiologist Know?

Contact Info

Product

Resources

About